Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey.

ABSTRACT: The Covid-19 pandemic required many clinical trials to adopt a decentralized framework to continue research activities during lock down restrictions. The STOPCoV study was designed to assess the safety and efficacy of Covid-19 vaccines in those aged 70 and above compared to those aged 30-50 years of age. In this sub-study we aimed to determine participant satisfaction for the decentralized processes, accessing the study website and collecting and submitting study specimens. The satisfaction survey was based on a Likert scale developed by a team of three investigators. Overall, there were 42 questions for respondents to answer. The invitation to participate with a link to the survey was emailed to 1253 active participants near the mid-way point of the main STOPCoV trial (April 2022). The re

SUBMITTER: Ravindran R 

PROVIDER: S-EPMC10168576 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature